DOCSLIB.ORG

Full Prescribing Information of Benlysta

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Full Prescribing Information of Benlysta HIGHLIGHTS OF PRESCRIBING INFORMATION • Subcutaneous Injection These highlights do not include all the information needed to use −Injection: 200 mg/mL single-dose prefilled autoinjector or single-dose BENLYSTA safely and effectively. See full prescribing information for prefilled syringe. (3) BENLYSTA. ----------------------------------- CONTRAINDICATIONS --------------------------------- BENLYSTA (belimumab) for injection, for intravenous use Previous anaphylaxis to belimumab. (4) BENLYSTA (belimumab) injection, for subcutaneous use Initial U.S. Approval: 2011 --------------------------- WARNINGS AND PRECAUTIONS -------------------------- • Serious Infections: Serious and sometimes fatal infections have occurred ------------------------------- RECENT MAJOR CHANGES------------------------------ in patients receiving immunosuppressive agents, including BENLYSTA. Indications and Usage (1) 12/2020 Use with caution in patients with severe or chronic infections. Consider Dosage and Administration (2.1, 2.2) 12/2020 interrupting therapy with BENLYSTA if patients develop a new Warnings and Precautions, Mortality (5.1) Removed- infection during treatment with BENLYSTA. (5.1) 09/2020 • Progressive Multifocal Leukoencephalopathy (PML): Evaluate patients Warnings and Precautions, Serious Infections (5.1) 09/2020 with new-onset or deteriorating neurological signs and symptoms for Warnings and Precautions, Depression and Suicidality (5.4) 09/2020 PML. If confirmed, consider discontinuation of immunosuppressant Warnings and Precautions, Concomitant Use with Other 12/2020 therapy, including BENLYSTA. (5.1) Biologic Therapies (5.7) • Hypersensitivity Reactions, including Anaphylaxis: Serious and fatal reactions have been reported. BENLYSTA for intravenous use should be -------------------------------- INDICATIONS AND USAGE ------------------------------ administered by healthcare providers prepared to manage anaphylaxis. BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated Monitor patients during infusion and for an appropriate period of time for the treatment of: after intravenous administration of BENLYSTA. (2.1, 5.2) • patients aged 5 years and older with active, autoantibody-positive • Depression and Suicidality: Depression and suicidality have been systemic lupus erythematosus (SLE) who are receiving standard therapy; reported in trials with BENLYSTA. Assess for depression and risk of (1) suicide before treatment with BENLYSTA and monitor during • adult patients with active lupus nephritis who are receiving standard treatment. Instruct patients to contact their healthcare provider if new or therapy. (1) worsening depression, suicidal thoughts, or other mood changes occur. • Limitations of Use: The efficacy of BENLYSTA has not been evaluated (5.4) in patients with severe active central nervous system lupus. BENLYSTA • Immunization: Live vaccines should not be given concurrently with has not been studied in combination with other biologics. Use of BENLYSTA. (5.6) BENLYSTA is not recommended in these situations. (1) ----------------------------------- ADVERSE REACTIONS---------------------------------- ---------------------------DOSAGE AND ADMINISTRATION ------------------------- • Common adverse reactions in adults (≥5%): nausea, diarrhea, pyrexia, • Intravenous Administration in Adults with SLE or Lupus Nephritis and nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, Pediatric Patients with SLE migraine, pharyngitis, and injection site reactions (subcutaneous −10 mg/kg at 2-week intervals for the first 3 doses and at 4-week administration). (6.1) intervals thereafter. Reconstitute, dilute, and administer as an • Adverse reactions in pediatric patients aged 5 years and older were intravenous infusion over a period of 1 hour. (2.1) consistent with those observed in adults. (6.2) −Consider administering premedication for prophylaxis against infusion reactions and hypersensitivity reactions. (2.1) To report SUSPECTED ADVERSE REACTIONS, contact • Subcutaneous Administration in Adults with SLE GlaxoSmithKline at 1-877-423-6597 or FDA at 1-800-FDA-1088 or −200 mg once weekly. (2.2) www.fda.gov/medwatch. • Subcutaneous Administration in Adults with Lupus Nephritis See 17 for PATIENT COUNSELING INFORMATION and Medication −See Section 2.2. Guide. ------------------------- DOSAGE FORMS AND STRENGTHS------------------------ Revised: 03/2021 • Intravenous Infusion −For Injection: 120 mg or 400 mg lyophilized powder in single-dose vials for reconstitution and dilution prior to intravenous infusion. (3) FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 7 DRUG INTERACTIONS 2 DOSAGE AND ADMINISTRATION 8 USE IN SPECIFIC POPULATIONS 2.1 Intravenous Preparation and Dosing Instructions 8.1 Pregnancy 2.2 Subcutaneous Dosing Instructions 8.2 Lactation 3 DOSAGE FORMS AND STRENGTHS 8.3 Females and Males of Reproductive Potential 4 CONTRAINDICATIONS 8.4 Pediatric Use 5 WARNINGS AND PRECAUTIONS 8.5 Geriatric Use 5.1 Serious Infections 8.6 Renal Impairment 5.2 Hypersensitivity Reactions, including Anaphylaxis 8.7 Hepatic Impairment 5.3 Infusion Reactions 8.8 Racial Groups 5.4 Depression and Suicidality 10 OVERDOSAGE 5.5 Malignancy 11 DESCRIPTION 5.6 Immunization 12 CLINICAL PHARMACOLOGY 5.7 Concomitant Use with Other Biologic Therapies 12.1 Mechanism of Action 6 ADVERSE REACTIONS 12.2 Pharmacodynamics 6.1 Clinical Trials Experience with Intravenous Administration 12.3 Pharmacokinetics 6.2 Clinical Trials Experience with Subcutaneous 13 NONCLINICAL TOXICOLOGY Administration in Adults 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 6.3 Postmarketing Experience 14 CLINICAL STUDIES 6.4 Immunogenicity 14.1 Clinical Trials with Intravenous Administration in Adults with SLE 14.2 Clinical Trials with Intravenous Administration in Adults with Lupus Nephritis 1 14.3 Clinical Trials with Intravenous Administration in Pediatric 16.2 Subcutaneous Injection Patients with SLE 17 PATIENT COUNSELING INFORMATION 14.4 Clinical Trials with Subcutaneous Administration in Adults *Sections or subsections omitted from the full prescribing information are not with SLE listed. 16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 Intravenous Infusion FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE BENLYSTA (belimumab) is indicated for the treatment of: • patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy, and • adult patients with active lupus nephritis who are receiving standard therapy. Limitations of Use The efficacy of BENLYSTA has not been evaluated in patients with severe active central nervous system lupus. BENLYSTA has not been studied in combination with other biologics. Use of BENLYSTA is not recommended in these situations. 2 DOSAGE AND ADMINISTRATION BENLYSTA may be administered as an intravenous infusion in patients aged 5 years and older or as a subcutaneous injection in patients aged 18 years and older. Vials are intended for intravenous use only (not for subcutaneous use) and autoinjectors and prefilled syringes are intended for subcutaneous use only (not for intravenous use). 2.1 Intravenous Preparation and Dosing Instructions Recommended Intravenous Dosage Regimen — Adults with SLE or Lupus Nephritis and Pediatric Patients with SLE BENLYSTA for intravenous use must be reconstituted and diluted prior to administration. Do not administer as an intravenous push or bolus. The recommended intravenous dosage regimen is 10 mg/kg at 2-week intervals for the first 3 doses and at 4-week intervals thereafter. Reconstitute, dilute, and administer as an intravenous infusion over a period of 1 hour. The infusion rate may be slowed or interrupted if the patient develops an infusion reaction. The infusion must be discontinued immediately if the patient experiences a serious hypersensitivity reaction [see Contraindications (4), Warnings and Precautions (5.2)]. Premedication Recommendations prior to Intravenous Use Prior to intravenous dosing with BENLYSTA, consider administering premedication for prophylaxis against infusion reactions and hypersensitivity reactions [see Warnings and Precautions (5.2, 5.3), Adverse Reactions (6.1)]. 2 Preparation of Intravenous Solutions BENLYSTA for intravenous use is provided as a lyophilized powder in a single-dose vial and should be reconstituted and diluted by a healthcare professional using aseptic technique as follows. Use of a 21- to 25-gauge needle is recommended when piercing the vial stopper for reconstitution and dilution. Reconstitution Instructions for Intravenous Use: 1. Remove the vial of BENLYSTA from the refrigerator and allow to stand for 10 to 15 minutes for the vial to reach room temperature. 2. Reconstitute the BENLYSTA powder with Sterile Water for Injection, USP, as follows. The reconstituted solution will contain a concentration of 80 mg/mL belimumab. • Reconstitute the 120-mg vial with 1.5 mL Sterile Water for Injection, USP. • Reconstitute the 400-mg vial with 4.8 mL Sterile Water for Injection, USP. 3. The stream of sterile water should be directed toward the side of the vial to minimize foaming. Gently swirl the vial for 60 seconds. Allow the vial to sit at room temperature during reconstitution, gently swirling the vial for 60 seconds every 5 minutes until the powder is dissolved. Do not shake. Reconstitution is typically complete within 10 to 15 minutes after the sterile water has been added, but it may take up to 30 minutes. Protect the reconstituted solution from sunlight. 4.
Load more

Recommended publications
  • BAFF-Neutralizing Interaction of Belimumab Related to Its Therapeutic Efficacy for Treating Systemic Lupus Erythematosus
    ARTICLE DOI: 10.1038/s41467-018-03620-2 OPEN BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus Woori Shin1, Hyun Tae Lee1, Heejin Lim1, Sang Hyung Lee1, Ji Young Son1, Jee Un Lee1, Ki-Young Yoo1, Seong Eon Ryu2, Jaejun Rhie1, Ju Yeon Lee1 & Yong-Seok Heo1 1234567890():,; BAFF, a member of the TNF superfamily, has been recognized as a good target for auto- immune diseases. Belimumab, an anti-BAFF monoclonal antibody, was approved by the FDA for use in treating systemic lupus erythematosus. However, the molecular basis of BAFF neutralization by belimumab remains unclear. Here our crystal structure of the BAFF–belimumab Fab complex shows the precise epitope and the BAFF-neutralizing mechanism of belimumab, and demonstrates that the therapeutic activity of belimumab involves not only antagonizing the BAFF–receptor interaction, but also disrupting the for- mation of the more active BAFF 60-mer to favor the induction of the less active BAFF trimer through interaction with the flap region of BAFF. In addition, the belimumab HCDR3 loop mimics the DxL(V/L) motif of BAFF receptors, thereby binding to BAFF in a similar manner as endogenous BAFF receptors. Our data thus provides insights for the design of new drugs targeting BAFF for the treatment of autoimmune diseases. 1 Department of Chemistry, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 05029, Republic of Korea. 2 Department of Bio Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Republic of Korea. These authors contributed equally: Woori Shin, Hyun Tae Lee, Heejin Lim, Sang Hyung Lee.
    [Show full text]
  • Ocrevus (Ocrelizumab) Policy Number: C11250-A
    Prior Authorization Criteria Ocrevus (ocrelizumab) Policy Number: C11250-A CRITERIA EFFECTIVE DATES: ORIGINAL EFFECTIVE DATE LAST REVIEWED DATE NEXT REVIEW DUE BY OR BEFORE 8/1/2017 2/17/2021 4/26/2022 LAST P&T J CODE TYPE OF CRITERIA APPROVAL/VERSION J2350-injection,ocrelizumab, Q2 2021 RxPA 1mg 20200428C11250-A PRODUCTS AFFECTED: Ocrevus (ocrelizumab) DRUG CLASS: Multiple Sclerosis Agents - Monoclonal Antibodies ROUTE OF ADMINISTRATION: Intravenous PLACE OF SERVICE: Specialty Pharmacy or Buy and Bill The recommendation is that medications in this policy will be for pharmacy benefit coverage and the IV infusion products administered in a place of service that is a non-hospital facility-based location (i.e., home infusion provider, provider’s office, free-standing ambulatory infusion center) AVAILABLE DOSAGE FORMS: Ocrevus SOLN 300MG/10ML FDA-APPROVED USES: Indicated for the treatment of: • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing- remitting disease, and active secondary progressive disease, in adults • Primary progressive MS, in adults COMPENDIAL APPROVED OFF-LABELED USES: None COVERAGE CRITERIA: INITIAL AUTHORIZATION DIAGNOSIS: Multiple Sclerosis REQUIRED MEDICAL INFORMATION: A. RELAPSING FORMS OF MULTIPLE SCLEROSIS: 1. Documentation of a definitive diagnosis of a relapsing form of multiple sclerosis as defined by the McDonald criteria (see Appendix), including: Relapsing- remitting multiple sclerosis [RRMS], secondary-progressive multiple sclerosis [SPMS] with relapses, and progressive- relapsing multiple sclerosis [PRMS] or First clinical episode with MRI features consistent with multiple sclerosis Molina Healthcare, Inc. confidential and proprietary © 2021 This document contains confidential and proprietary information of Molina Healthcare and cannot be reproduced, distributed, or printed without written permission from Molina Healthcare.
    [Show full text]
  • Intravenous Therapy Procedure Manual
    INTRAVENOUS THERAPY PROCEDURE MANUAL - 1 - LETTER OF ACCEPTANCE __________________________________________ hereby approves (Facility) the attached Reference Manual as of _____________________. (Date) The Intravenous Therapy Procedure Manual will be reviewed at least annually or more often when deemed appropriate. Revisions will be reviewed as they occur. Current copies of the Intravenous Therapy Procedure Manual shall be maintained at each appropriate nursing station. I have reviewed this manual and agree to its approval. __________________________ (Administrator) __________________________ (Director of Nursing) __________________________ (Medical Director) - 2 - TABLE OF CONTENTS TABLE OF CONTENTS INTRODUCTION A. Purpose 1 B. Local Standard of Practice 1 RESPONSIBILITIES A. Responsibilities: M Chest Pharmacy 1 B. Responsibilities: Administrator 1 C. Responsibilities: Director of Nursing Services (DON/DNS) 1 D. Skills Validation 2 AMENDMENTS GUIDELINES A. Resident Candidacy for IV Therapy 1 B. Excluded IV Medications and Therapies 1 C. Processing the IV Order 1 D. IV Solutions/Medications: Storage 2 E. IV Solutions/Medications: Handling 3 F. IV Solutions and Supplies: Destroying and Returning 4 G. IV Tubing 5 H. Peripheral IV Catheters and Needles 6 I. Central Venous Devices 7 J. Documentation and Monitoring 8 K. IV Medication Administration Times 9 L. Emergency IV Supplies 10 I TABLE OF CONTENTS PROTOCOLS A. IV Antibiotic 1 1. Purpose 2. Guidelines 3. Nursing Responsibilities B. IV Push 2 1. Purpose 2. Guidelines C. Anaphylaxis Allergic Reaction 4 1. Purpose 2. Guidelines 3. Nursing Responsibilities and Interventions 4. Signs and Symptoms of Anaphylaxis 5. Drugs Used to Treat Anaphylaxis 6. Physician Protocol PRACTICE GUIDELINES A. Purpose 1 B. Personnel 1 C. Competencies 1 D.
    [Show full text]
  • Exploring the Association Between Monoclonal Antibodies and Depression and Suicidal Ideation and Behavior: a Vigibase Study
    Drug Safety https://doi.org/10.1007/s40264-018-00789-9 ORIGINAL RESEARCH ARTICLE Exploring the Association between Monoclonal Antibodies and Depression and Suicidal Ideation and Behavior: A VigiBase Study Lotte A. Minnema1,2 · Thijs J. Giezen2,3 · Patrick C. Souverein1 · Toine C. G. Egberts1,4 · Hubert G. M. Leufkens1 · Helga Gardarsdottir1,4,5 © The Author(s) 2019 Abstract Introduction Several monoclonal antibodies (mAbs) have been linked to neuropsychiatric adverse efects in patients, includ- ing depression and suicidal ideation and behavior. Objective The aim of this study was to quantify and characterize spontaneously reported adverse drug reactions (ADRs) of depression and suicidal ideation and behavior related to mAb users, and to explore a possible association with their mecha- nism of action. Methods We included mAb ADRs that were reported in VigiBase, and identifed those related to depression and suicidal ideation and behavior. Reporting odds ratios (RORs) were estimated for each mAb (bevacizumab as the reference) and according to their infuence on the immune system (not directly targeting [reference], stimulating, or suppressing). Those suppressing the immune system were further divided into their intended indication (auto-immune diseases, cancer). Results Overall, 2,924,319 ADRs for 44 mAbs were included; 9455 ADRs were related to depression and 1770 were related to suicidal ideation and behavior. The association was strongest for natalizumab and belimumab, both for depression (ROR 5.7, 95% confdence interval [CI] 5.0–6.4; and ROR 5.1, 95% CI 4.2–6.2) and suicidal ideation and behavior (ROR 12.0, 95% CI 7.9–18.3; and ROR 20.2, 95% CI 12.4–33.0).
    [Show full text]
  • Curriculum Vitae: Daniel J
    CURRICULUM VITAE: DANIEL J. WALLACE, M.D., F.A.C.P., M.A.C.R. Up to date as of January 1, 2019 Personal: Address: 8750 Wilshire Blvd, Suite 350 Beverly Hills, CA 90211 Phone: (310) 652-0010 FAX: (310) 360-6219 E mail: [email protected] Education: University of Southern California, 2/67-6/70, BA Medicine, 1971. University of Southern California, 9/70-6/74, M.D, 1974. Postgraduate Training: 7/74-6/75 Medical Intern, Rhode Island (Brown University) Hospital, Providence, RI. 7/75-6/77 Medical Resident, Cedars-Sinai Medical Center, Los Angeles, CA. 7/77-6/79 Rheumatology Fellow, UCLA School of Medicine, Los Angeles, CA. Medical Boards and Licensure: Diplomate, National Board of Medical Examiners, 1975. Board Certified, American Board of Internal Medicine, 1978. Board Certified, Rheumatology subspecialty, 1982. California License: #G-30533. Present Appointments: Medical Director, Wallace Rheumatic Study Center Attune Health Affiliate, Beverly Hills, CA 90211 Attending Physician, Cedars-Sinai Medical Center, Los Angeles, 1979- Clinical Professor of Medicine, David Geffen School of Medicine at UCLA, 1995- Professor of Medicine, Cedars-Sinai Medical Center, 2012- Expert Reviewer, Medical Board of California, 2007- Associate Director, Rheumatology Fellowship Program, Cedars-Sinai Medical Center, 2010- Board of Governors, Cedars-Sinai Medical Center, 2016- Member, Medical Policy Committee, United Rheumatology, 2017- Honorary Appointments: Fellow, American College of Physicians (FACP) Fellow, American College of Rheumatology (FACR)
    [Show full text]
  • Migraine Specialty Care Program Tm
    MIGRAINE SPECIALTY CARE PROGRAM TM Phone: 833-796-6470 • Fax: 844-841-3401 Community Led Specialty Pharmacy Care 1 PATIENT INFORMATION: 2 PRESCRIBER INFORMATION: Name: ___________________________________________________ Name: ___________________________________________________ Address: _________________________________________________ Address: _________________________________________________ City: _________________________ State: ____ Zip: ____________ City: _________________________ State: ____ Zip: ____________ Phone: ___________________ Alt. Phone: ____________________ Phone: _____________________ Fax: _______________________ Email: ____________________________________________________ NPI: ________________________ DEA: _______________________ DOB: ___________ Gender: M F Caregiver: _____________ Tax I.D.: __________________________________________________ Height: ________ Weight: ________ Allergies: ________________ Office Contact: __________________ Phone: __________________ 3 STATEMENT OF MEDICAL NECESSITY: (Please Attach All Medical Documentation) Prior Failed Indicate Drug Name v10.0_060821 Length of Symptoms: ___________________________ ICD-10: _________________________ Treatments: and Length of Treatment: Other diagnosis _______________ Number of Migraine Days per month: ________________ Preventative: Headache Days per month: _________________ Migraine Hours per day: __________________ ACE-I/ARBs ___________________ Patient has been evaluated and does not have medication overuse headache? No Yes Antiepileptics ___________________
    [Show full text]
  • Attachment 3
    CURRICULUM CLINICAL BASE / CA-1 / CA-2 / CA-3 ANESTHESIOLOGY RESIDENCY PROGRAM GOALS AND OBJECTIVES AND CORE COMPETENCIES Department of Anesthesiology University of Missouri at Kansas City School of Medicine Saint Luke’s Hospital Truman Medical Center Children’s Mercy Hospital Revised 2011 Table of Contents Pages Introduction – Statement of Curriculum ................................................................................................................... 3 I. Rendering Patient Insensible to Pain ............................................................................................................. 4-10 II. Support of Life Functions ............................................................................................................................. 11-16 III. Clinical Base Year A. Cardiology ................................................................................................................................................. 17-32 B. Emergency Medicine ................................................................................................................................. 33-44 C. General Medicine ....................................................................................................................................... 45-49 D. Infectious Disease ...................................................................................................................................... 50-59 E. Nephrology ..............................................................................................................................................
    [Show full text]
  • DDT Cover/Back April 2006.Qx
    March 2007 Vol 7 No 3 www.drugdeliverytech.com IN THIS ISSUE INTERVIEW WITH DPT’S PRESIDENT MR. PAUL JOHNSON In Situ Gel Systems 30 Mitan Gokulgandhi, BPharm Dharmesh M. Modi, MPharm COX-II Microspheres 38 Lakshmi Sivasubramanian Madhumathi Seshadri Undermining CEO’s 82 John A. Bermingham FEATURING Parkinson’s Disease 59 Steven Damon Yogi R. Patel The science & business of specialty pharma, biotechnology, and drug delivery Specialty Pharma Indices 64 Dr. Barath Christopher Avani Amin, Josef Bossart, PhD Shankar Robinson, PhD Drug Delivery’s PhD Current Status of Clinical Trials Increasing New Ways to Non-Invasive In Asia 68 Importance to Partner With Insulin Delivery Ames Gross, MBA Big Pharma & the Federal Technologies Specialty Pharma Government Momoko Hirose March 2007 Vol 7 No 3 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel: (703) 212-7735 Fax: (703) 548-3733 E-mail: [email protected] E-mail: [email protected] West Coast Warren
    [Show full text]
  • Nicotine Patches Appear Safe for CAD Patients
    May 1, 2007 • www.internalmedicinenews.com Cardiovascular Medicine 37 Nicotine Patches Appear Safe for CAD Patients BY BRUCE JANCIN 30%, but many physicians have been re- induced myocardial defect on single-photon ment arm jumped from 10.9 to 25.2 Denver Bureau luctant to recommend it for their patients emission computed tomography (SPECT) ng/mL, Dr. Leja said. After 1 week, patients with coronary artery disease (CAD) be- to receive either 21-mg nicotine patches or were encouraged to quit smoking while N EW O RLEANS — Nicotine patches cause nicotine is known to increase heart placebo in addition to continuing their usu- continuing to use their assigned patches. are safe for use in smokers with known rate and blood pressure, and can induce al amount of cigarette smoking. The pri- Upon SPECT imaging at week 4, the coronary artery disease and stress-induced vasoconstriction as well, Dr. Monika J. Leja mary end point of the study was change in size of the perfusion defects in the nico- myocardial ischemia, according to the re- reported at the annual scientific session of total perfusion defect size upon repeat stress tine patch group remained unchanged sults of the first-ever randomized, place- the American College of Cardiology. SPECT imaging performed at 1 week. from baseline, although their plasma nico- bo-controlled, multicenter clinical trial to Dr. Leja and her coinvestigators at the There was no change in the total or is- tine levels remained as high as at week 1. examine this issue. Methodist DeBakey Heart Center in Hous- chemic perfusion defect size, compared The trial was supported by Glaxo- Nicotine replacement therapy doubles ton randomized 55 heavy smokers with with baseline, in either group even though SmithKline Consumer Healthcare.
    [Show full text]
  • Medication Permission Form
    CHARDON LOCAL SCHOOLS MEDICATION PERMISSION FORM Student Name :__________________________________________ Grade/Class _______ Teacher :______________________ School ____________________ Student Address:____________________________________________________________________________ Date of Birth____________________________ TO BE COMPLETED BY HEALTH CARE PROVIDER Please print clearly and complete ALL sections. Time/Frequency Adverse Reaction to Report to (Include minimum time Physician and/or Special Name of Medication Dose Route (circle) Interval for prn dosing) Reason for Medication Start Date Stop Date Instructions Tablet/Capsule PO Liquid PO _________________ __/__/__ ___/___/___ Inhaler/Nebulizer OR OR Other__________ As needed every __hrs. ___ End of School year Tablet/Capsule PO Liquid PO _________________ __/__/__ ___/___/___ Inhaler/Nebulizer OR OR Other__________ As needed every __hrs ___ End of School year EPINEPHRINE AUTOINJECTOR Not Applicable SELF -CARRY AUTHORIZATION Yes, as the prescriber I have determined that this student is capable of possessing and using this autoinjector appropriately and have provided the student with training in the proper use of the autoinjector. ASTHMA INHALER Not Applicable SELF -CARRY AUTHORIZATION Yes, as the prescriber I have determined that this student to capable of possessing and using this inhaler appropriately and have provided the student with training in the proper use of the inhaler. Reminder note for prescriber: ORC 3313.718 requires backup epinephrine autoinjector and best practice recommends backup asthma inhaler Health Care Provider Name _______________________________________ Health Care Provider Signature: ______________________________________ Date_________________ Phone Number: _______________________________________ Fax Number: _________________________________________ TO BE COMPLETED BY PARENT OR GUARDIAN I authorize an employee of the school board to administer the above medication. I understand that additional parent/prescriber signed statements will be necessary if the dosage of medication is changed.
    [Show full text]
  • Intravenous Infusion Drug Administration: Flushing Guidance
    Intravenous Infusion Drug Administration: Flushing Guidance April 2019 Acknowledgements: Andrew Barton – Author/reviewer NIVAS Chair Advanced Nurse Practitioner, IV Therapy and Vascular Access Frimley Health NHS Foundation Trust Tim Jackson – Reviewer/contributor, NIVAS Board Deputy Chair Consultant in Anesthesia & Intensive Care Medicine Calderdale & Huddersfield NHS Foundation Trust Gemma Oliver - Reviewer/contributor NIVAS Board Nurse Consultant, Integrated IV Care East Kent Hospitals NHS Foundation Trust Nicola York - Reviewer/contributor NIVAS Board Clinical Nurse Manager Vascular Access and Nutrition support Oxford University Hospitals NHS Foundation Trust Matt Jones - Reviewer/contributor NIVAS Board Consultant Anaesthetist East Kent Hospitals NHS Foundation Trust Steve Hill - Reviewer/contributor NIVAS Board Procedural Team Manger The Christie NHS Foundation Trust Marie Woodley - Reviewer/contributor NIVAS Board Clinical Nurse Specialist IV therapy/OPAT Lead Buckinghamshire Healthcare Trust Contents: Introduction………………………………………………………………………… Page 1 Methods of administering intravenous therapy………………………………… Page 2 Intravenous bolus injection…………………………………………….… Page 2 Continuous, variable dose syringe driver injection……………………. Page 2 Intravenous infusion…………………………………………………….… Page 3 Option 1: Discarding the infusion set………………………………….… Page 3 Option 2: Flushing the Infusion set manually…………………………... Page 4 Option 3: Flushing the infusion set with a closed system…………….. Page 4 General Guidance…………………………………………………………………. Page 5 Conclusion………………………………………………………………………….
    [Show full text]
  • Intravenous Therapytherapy
    IntravenousIntravenous TherapyTherapy Department of EMS Professions Temple College IVIV TherapyTherapy OverviewOverview I DefinitionsDefinitions && IndicationsIndications I FluidFluid ResuscitationResuscitation I EquipmentEquipment andand SuppliesSupplies I ChoosingChoosing FluidsFluids andand CathetersCatheters I ProcedureProcedure andand TechniqueTechnique TipsTips – Peripheral Venipuncture – Intraosseous Access I PotentialPotential ComplicationsComplications DefinitionsDefinitions I IVIV // VenipunctureVenipuncture I CrystalloidsCrystalloids I PeripheralPeripheral // CentralCentral I ColloidsColloids I IntraosseousIntraosseous AccessAccess I HypertonicHypertonic I FluidFluid ResuscitationResuscitation I IsotonicIsotonic I MedicationMedication AccessAccess I DripDrip RatesRates I KVOKVO // TKOTKO IndicationsIndications forfor VenipunctureVenipuncture I VolumeVolume I VenousVenous AccessAccess toto – Dehydration CirculationCirculation I Water – Blood collection I Electrolytes I Labs – Blood Loss I Field Chemistry I Colloids – Medication I Crystalloids Administration FluidFluid ResuscitationResuscitation I DehydrationDehydration andand I ShockShock VolumeVolume LossLoss ManagementManagement – Replace Lost Fluid or – Controversial Blood – Definitive therapy = – Often requires 2 -3 Surgery and blood times the amount replacement lost (2:1 rule) – EMS → judicious replacement – Improve end organ perfusion (BP at 90 - 100 mm Hg) EquipmentEquipment andand SuppliesSupplies I FluidsFluids I SuppliesSupplies – Normal Saline – IV Catheters (0.9%
    [Show full text]